# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jacqueline du Pré (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML039-SYN-TD
- Date: 1973-07-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Imogen Thackeray-Osei, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three months on ocrelizumab: re-baseline MRI review. **S**

## History of present illness

Ms. du Pré returns three months after her first ocrelizumab infusion, after a re-baseline MRI five days ago. The cystitis four weeks ago cleared with nitrofurantoin, and the tingling that came back with the fever went within two days of it. She has had no new symptoms. Feeling in her fingers is almost normal except after long practice, and she practices three hours a day. She has started swimming twice a week, which helps the fatigue, and rests after lunch. She played a private recital for friends last week. She takes cholecalciferol daily. **S**

| Element | Detail |
|---|---|
| Disease activity | No relapse since starting ocrelizumab; re-baseline MRI with no new or enhancing lesions |
| Intercurrent illness | Cystitis with a pseudo-relapse four weeks ago, resolved |
| Hand function | Practicing three hours a day; private recital last week |
| Fatigue | Better with swimming, pacing and an after-lunch rest |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Mild late-afternoon fatigue; no fever |
| Neurological | Positive | Faint tingling in the left fingertips after long practice; no new symptoms |
| Genitourinary | Negative | No urinary symptoms since the cystitis |
| Respiratory | Negative | No cough |
| Integumentary | Negative | No rash |
| Psychiatric | Negative | Mood good; PHQ-9 4; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily **S**
- Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 64 kg; BMI 21.4 kg/m². All vital signs are synthetic.

Hemoglobin: 13.5 g/dL; White cell count: 6.1 10*3/uL; Lymphocytes: 1.5 10*3/uL; Platelets: 240 10*3/uL; CD19 B cells: 3 /uL (low); IgG: 990 mg/dL; 25-hydroxyvitamin D: 34 ng/mL; PHQ-9: 4; Nine-hole peg test, right hand: 19 s; Nine-hole peg test, left hand: 20.5 s. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.4 g/dL at baseline, 13.5 g/dL at this visit **S**
- White cell count: 6.4 10*3/uL at baseline, 6.1 10*3/uL at this visit **S**
- Lymphocytes: 1.9 10*3/uL at baseline, 1.5 10*3/uL at this visit **S**
- Platelets: 246 10*3/uL at baseline, 240 10*3/uL at this visit **S**
- Nine-hole peg test, right hand: 26 s at baseline, 19 s at this visit **S**
- Nine-hole peg test, left hand: 33.5 s at baseline, 20.5 s at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 64.0 kg; blood pressure 110/70 |
| Neurological | Vibration slightly reduced in the left fingertips only; joint position, strength, reflexes and gait normal; no Lhermitte's sign. Nine-hole peg test 19.0 seconds right, 20.5 seconds left. EDSS 1.0 |
| Psychiatric | Bright, warm and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Relapsing-remitting multiple sclerosis, on ocrelizumab** (G35.A). No relapse and no new or enhancing lesions on the re-baseline MRI, which becomes the reference for future scans; the June episode was a pseudo-relapse with infection, not a relapse. Hand function nearly normal (nine-hole peg 19.0 and 20.5 seconds) and EDSS 1.0. B cells are depleted (CD19 3 per microliter), as expected, and IgG is normal. The hepatitis B surface antibody check due after her two vaccine doses was missed. **S**
   - Recombinant zoster vaccine dose 2 today.
   - Ocrelizumab 600 mg in three months, with blood count, immunoglobulins, hepatitis B surface antibody and a pregnancy test beforehand.
   - MRI of the brain yearly from now.
2. **Vitamin D deficiency** (E55.9). 25-hydroxyvitamin D 34 ng/mL after 16 weeks: corrected. **S**
   - Continue cholecalciferol 4000 units daily.
3. **Acute cystitis with a pseudo-relapse** (N30.00). Resolved with nitrofurantoin; no recurrence. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Re-baseline MRI of the brain | Three to six months after starting a disease-modifying therapy, then yearly | Up to date | Five days ago: no new or enlarging T2 lesions, no enhancement |
| Laboratory | Blood count with lymphocytes | Every three to six months on ocrelizumab | Completed today | Hemoglobin 13.5 g/dL, white cells 6.1, lymphocytes 1.5, platelets 240 |
| Laboratory | CD19 B-cell count | When needed to confirm depletion | Completed today | 3 per microliter: depleted, as expected |
| Laboratory | Immunoglobulins (IgG, IgM) | At baseline and before each ocrelizumab dose | Completed today | IgG 990 mg/dL |
| Laboratory | 25-hydroxyvitamin D | About three months after starting replacement | Completed today | 34 ng/mL |
| Laboratory | Hepatitis B surface antibody after vaccination | One to two months after the last dose, for people on immunosuppressive therapy | Deferred | Missed: the antibody check due one to two months after the second hepatitis B dose was not ordered. No harm is expected in the meantime, since she has no hepatitis B exposure; corrective action: added to the blood tests before the next ocrelizumab dose, and post-vaccination serology added to the clinic's B-cell therapy checklist |
| Medication safety | Vaccination | Complete series where possible | Completed today | Recombinant zoster dose 2 today |
| Medication safety | Infections on anti-CD20 therapy | Each review | Completed today | One uncomplicated cystitis, treated; no other infection |
| Examination | Hand function: nine-hole peg test, both hands | At diagnosis, after a relapse, and at each review | Completed today | 19.0 seconds right, 20.5 seconds left |
| Examination | Neurological examination and EDSS | Each review | Completed today | EDSS 1.0 |
| Survey | Mood and anxiety (PHQ-9, GAD-7) | At diagnosis and at each review | Completed today | PHQ-9 4; item 9 scored 0 |
| Self-management | Fatigue: causes and management | Each review | Completed today | Aerobic exercise (swimming), pacing and rest; no medicine needed |

## Goal progress

- MRI of the brain and spine within one week and a neurology diagnosis within three weeks. Outcome by 1973-03-23: MRI in three days, lumbar puncture in a week, diagnosis and consultation at two weeks. **S**
- High-efficacy disease-modifying therapy started within six weeks of diagnosis, after screening and vaccinations. Outcome by 1973-04-27: Ocrelizumab started three weeks after the diagnosis; PCV20, recombinant zoster and hepatitis B vaccines given first. **S**
- Nine-hole peg times back to within 10 percent of normal in both hands, and full practice resumed. Outcome by 1973-07-13: 19.0 seconds right and 20.5 seconds left at three months; practicing three hours a day. **S**
- No evidence of disease activity at six months (no relapse, no new or enhancing MRI lesion, no disability progression). In progress; target 1973-10-12. **S**
- 25-hydroxyvitamin D of 30 ng/mL or more. Outcome by 1973-07-13: 34 ng/mL after 16 weeks of cholecalciferol. **S**
- PHQ-9 below 10 throughout. In progress; target 1973-10-12. **S**

## Guideline basis

- Rae-Grant A, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90(17):777-788 (PMID 29686116) (2018), American Academy of Neurology
- Montalban X, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24(2):96-120 (PMID 29353550) (2018), European Committee for Treatment and Research in Multiple Sclerosis / European Academy of Neurology
- Multiple sclerosis in adults: management (NICE guideline NG220) (2022), National Institute for Health and Care Excellence
- Wattjes MP, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20(8):653-670 (PMID 34139157) (2021), The Lancet Neurology
- Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019), American Academy of Neurology

## Follow-up

- Ocrelizumab 600 mg in three months with blood tests beforehand; preventive visit due; call for fever, urinary symptoms or any new neurological symptom. **S**
- Next scheduled visit 1973-09-14: periodic adult preventive visit on B-cell therapy. **S**
